AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi

Blood

Volumn 111, Issue 8, 2008, Pages 4297-4308

  Watanabe Okochi, Naoko ^a   Kitaura, Jiro ^a   Ono, Ryoichi ^a   Harada, Hironori ^b   Harada, Yuka ^b   Komeno, Yukiko ^a   Nakajima, Hideaki ^a   Nosaka, Tetsuya ^a   Inaba, Toshiya ^b   Kitamura, Toshio ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE SURFACE MARKER; TRANSCRIPTION FACTOR RUNX1; DNA BINDING PROTEIN; EVI1 PROTEIN, MOUSE; MUTANT PROTEIN; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; GENE MUTATION; HEMATOPOIETIC STEM CELL; HEPATOSPLENOMEGALY; LEUKOCYTOSIS; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PANCYTOPENIA; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SOUTHERN BLOTTING; WESTERN BLOTTING; ANIMAL; BLOOD CELL COUNT; C57BL MOUSE; CANCER INVASION; CELL LINEAGE; CELL STRAIN 3T3; CHEMISTRY; DISEASE MODEL; ERYTHROID CELL; GENETIC TRANSDUCTION; GENETICS; HUMAN; LEUKOPENIA; METABOLISM; MUTATION; PATHOLOGY; PROTO ONCOGENE; SPLEEN;

ANIMALS; BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; CELL LINEAGE; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ERYTHROID CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTOSIS; LEUKOPENIA; MICE; MICE, INBRED C57BL; MUTANT PROTEINS; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; PANCYTOPENIA; PROTO-ONCOGENES; SPLEEN; TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC;

EID: 43249103972     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-01-068346     Document Type: Article

References (52)

1. Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Am Soc Hematol Educ Program. 2003;176-199.
2. Heaney ML Golde DW. Myelodysplasia. N Engl J Med. 1999;340:1649-1660.
3. Legare RD, Gilliland DG. Myelodysplastic syndrome. Curr Opin Hematol. 1995;2:283-292.
4. Hirai H, Kobayashi Y, Mano H, et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature. 1987;327:430-432.
5. Hirai H, Okada M, Mizoguchi H, et al. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression myelodysplastic syndrome. Blood. 1988;71:256-258.
6. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol. 2002;9:274-281.
7. Schessl C, Rawat VP, Cusan M, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest. 2005;115:2159-2168.
8. Okuda T, Cai Z, Yang S, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998;91:3134-3143.
9. Rhoades KL, Hetherington CJ, Harakawa N. et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 2000;96:2108-2115.
10. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63-74.
11. Fenske TS, Pengue G, Mathews V, et al. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci U S A. 2004;101:15184-15189.
12. de Guzman CG, Warren AJ, Zhang Z, et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol. 2002;22:5506-5517.
13. Ono R, Nakajima H, Ozaki K, et al. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest. 2005;115:919-929.
14. Buonamici S, Li D, Chi Y, et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest. 2004;114:713-719.
15. Lin YW, Slape C, Zhang Z, Apian PD. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood. 2005;106:287-295.
16. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential tor normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
17. Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hematorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996;93:3444-3449.
18. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10:299-304.
19. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166-175.
20. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364-1372.
21. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93:1817-1824.
22. Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 2000;96:2862-2869.
23. Imai Y, Kurokawa M, Izutsu K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood. 2000;96:3154-3160.
24. Langabeer SE, Gale RE, Rollinson SJ, Morgan GJ, Linch DC. Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7. Genes Chromosomes Cancer. 2002;34:24-32.
25. Harada H, Harada Y, Tanaka H, KimuraA, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood. 2003;101:673-680.
26. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004;103:2316-2324.
27. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23:4284-4296.
28. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005;74:47-53.
29. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood. 2004;104:1474-1481.
30. Yamashita N, Osato M, Huang L, et al. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol. 2005;131:495-507.
31. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988;54:831-840.
32. Mucenski ML, Taylor BA, Ihle JN, et al. Identification of a common ecotropic viral integration site, Evi1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol. 1988;8:301-308.
33. Calmels B, Ferguson C, Laukkanen MO, et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood. 2005;106:2530-2533.
34. Kustikova O, Fehse B, Modlich U, et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 2005;308:1171-1174.
35. Modlich U, Kustikkova OS, Schmidt M, et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005;105:4235-4246.
36. Nucifora G, Laricchia-Robbio L, Senyuk V. Evil and hematopoietic disorders: history and perspectives. Gene. 2006;368:1-11.
37. Akagi K. Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTGGD: retroviral tagged cancer gene database. Nucleic Acids Res. 2004;32:523-527.
38. Jin G, Yamazaki Y, Takuwa M, et al. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood. 2007;109:3998-4005.
39. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7:1063-1066.
40. Kitamura T, Koshino Y, Shibata F, et al. 2003. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp. Hematol. 2003;31:1007-1014.
41. Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100:238-245.
42. Slape C, Hartung H, Lin YW, et al. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res. 2007;67:5148-55.
43. Wimmer K, Vinatzer U, Zwirn P, et al. Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation. Biochem Biophys Res Commun. 1998;252:691-6.
44. Riley J, Butler R, Ogilvie D, et al. A novel rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clones. Nucl. Acids Res. 1990;18:2887-2890.
45. Arnold C, Hodgson IJ. Vectorette PCR: a novel approach to genome walking. PCR Methods Appl. 1991;1:39-42.
46. Tsuzuki S, Hong D, Gupta R, Matsuo K, Seto M, Enver T. Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS Med. 2007;4:e172.
47. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A. 1995;92:6733-6737.
48. Langabeer SE, Rogers JR, Harrison G, et al. EVI1 expression in acute myeloid leukaemia. Br J Haematol. 2001;112:208-211.
49. Cuenco GM, Ren R. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. Oncogene. 2004;23:569-579.
50. Louz D, van den Broek M, Verbakel S, et al. Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice. Leukemia. 2000;14:1876-1884.
51. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006;108:3898-905.
52. Cuenco GM, Nucifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci USA. 2000;97:1760-1765.